Silver Book Fact

The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but no optic, disc or visual field deterioration.

Kass M, Heuer D, Higginbotham E, Johnson C, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13. http://archopht.ama-assn.org/cgi/content/abstract/120/6/701

Reference

Title
The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Publication
Archives of Ophthalmology
Publication Date
2002
Authors
Kass M, Heuer D, Higginbotham E, Johnson C, et al.
Volume & Issue
Volume 120, Issue 6
Pages
701-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • After 9 years of tight blood pressure control, patients with type 2 diabetes had a 34% reduction in retinopathy progression and a 47% reduction in risk of visual acuity deterioration…  
  • Tele-ophthalmology
    Adequately trained general practitioners can screen for DR with 90% sensitivity using tele-ophthalmology.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).